Roivant Sciences (ROIV) CEO Eric Venker Sells $7M of Stock
Key Points
- Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., sold 200,000 shares on October 20, 2026, valued at approximately $7.02 million.
- The planned sale left the insider with 1,399,154 shares remaining in his direct account.
- Roivant Sciences trades on the NasdaqGS under the ticker ROIV with its next earnings update scheduled for November 9, 2026.
Since the trade, $ROIV is up 7.2% to date (from the $34.92 close on Oct 20, 2026).
Get Roivant Sciences Ltd. text alerts
We text you when insiders, Congress, analysts or big funds move on $ROIV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Roivant Sciences Ltd. alert may contain errors. Disclosures
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., sold 200,000 shares of the company on October 20, 2026. According to a Form 4 filing with the U.S. Securities and Exchange Commission, the shares were disposed of at an average price of $35.11 for a total transaction value of about $7.02 million.
ROIV
Roivant Sciences Ltd.
Inside Eric Venker's Roivant Sciences Trade
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Venker directly holds 1,399,154 shares of Roivant Sciences, which marks a 12.51% reduction in his personal stake. On the day of the trade, Roivant Sciences shares closed at $34.92.
Other Institutional Activity in Roivant Sciences
Other institutional investors have adjusted their positions in Roivant Sciences recently. IFM Investors picked up a new stake by adding 128,826 shares, ending with 128,826 shares worth about $4.71 million. QVT Financial LP trimmed its holdings by 1,439,287 shares, leaving it with 23,723,074 shares valued at about $888.43 million. Farallon Capital Management LLC grew its position by 4,634,220 shares to finish with 14,309,000 shares worth about $535.87 million.
Roivant Sciences Ltd. Stock Up 1.8%
Recent trading put the stock around $37.45 as of October 22, 2026, which is up about 7.2% compared to its close on the transaction date. The shares sit above both their 50-day moving average and their 200-day moving average.
Recent Earnings
Roivant Sciences reported trailing-twelve-month revenue of $7.53 million alongside a net margin of 0.0% and an earnings per share of -$0.53. The company operates with a negative return on equity of 8.5%, and its next earnings report is slated for November 9, 2026.
Dividend
Roivant Sciences does not pay a dividend to shareholders.
Insider Buying and Selling at Roivant Sciences Ltd.
Prior insider transactions at the company include a sale by Keith Manchester of 800,000 shares for $27.64 million on June 29, 2026, followed by smaller sales from Qvt Financial LP and Daniel Allen Gold on June 30, 2026.
Analysts Set New Price Targets
Wall Street firms have active coverage on ROIV. On September 8, 2026, HC Wainwright & Co. maintained a Buy rating with a $47.00 price target. TD Cowen kept a Buy rating with a $55.00 target on September 9, 2026, while Guggenheim held a Buy rating with a $46.00 target on the same day. Stifel initiated coverage with a Buy rating and a $51.00 target on September 17, 2026. Later, Wolfe Research downgraded the stock to Peer Perform on October 12, 2026. Overall, the stock carries a consensus recommendation of strong buy.
About Roivant Sciences
Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company based in London, United Kingdom, focused on discovering, developing, and commercializing medicines and technologies through various subsidiary ventures.
Bottom Line
Investors tracking insider moves can monitor future SEC filings to see if other executives adjust their holdings. The company's upcoming earnings release on November 9, 2026, will provide fresh financial details.
Related Filing Alerts
Source: Eric Venker's Form 4 filing on $ROIV (Oct 20, 2026). Written by software, not financial advice. How we make alerts